VARSHA V GANDHI to Arabinofuranosylcytosine Triphosphate
This is a "connection" page, showing publications VARSHA V GANDHI has written about Arabinofuranosylcytosine Triphosphate.
Connection Strength
0.938
-
Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res. 1997 Sep; 3(9):1539-45.
Score: 0.153
-
Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia. 1994 Sep; 8(9):1463-8.
Score: 0.125
-
Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma. 1993; 10 Suppl:109-14.
Score: 0.111
-
Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood. 1989 Nov 01; 74(6):2070-5.
Score: 0.089
-
Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988 Jan 15; 48(2):329-34.
Score: 0.079
-
Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther. 2007 Dec; 323(3):935-45.
Score: 0.077
-
Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia. Clin Cancer Res. 1998 Jul; 4(7):1719-26.
Score: 0.041
-
Intracellular pharmacodynamics in leukemia therapy. Rinsho Ketsueki. 1996 May; 37(5):369-79.
Score: 0.035
-
Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res. 1996 Apr; 2(4):653-8.
Score: 0.035
-
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 1996 Jan 01; 87(1):256-64.
Score: 0.034
-
Modulation of arabinosylcytosine metabolism during leukemia therapy. Adv Exp Med Biol. 1994; 370:119-24.
Score: 0.030
-
Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol. 1994; 34(1):30-6.
Score: 0.030
-
Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells. Cancer Chemother Pharmacol. 1992; 31(1):11-7.
Score: 0.026
-
Metabolism and action of 2',2'-difluorodeoxycytidine: self-potentiation of cytotoxicity. Adv Exp Med Biol. 1991; 309A:125-30.
Score: 0.024
-
Interaction of arabinosyl nucleotides in K562 human leukemia cells. Biochem Pharmacol. 1989 Oct 15; 38(20):3551-8.
Score: 0.022
-
Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol. 2002 Oct 15; 20(20):4217-24.
Score: 0.014
-
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996 Oct; 10(10):1563-9.
Score: 0.009
-
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. Leukemia. 1987 Sep; 1(9):638-43.
Score: 0.005